Enveric Biosciences Earning Date (ENVB)

USA |NASDAQ |USD

ENVB Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
- Dec 31, 2021 - $-0.12 -
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
- Dec 31, 2021 - $0.00 $-26.34M

ENVB Earnings Date & History Chart

ENVB Earnings & Revenue Forecast

ENVB Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Mar 2022 1 $-0.15 $-0.15 $-0.15
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $-0.60 $-0.60 $-0.60

ENVB Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Mar 2022 0 / 0 $-0.15 $-0.15 $-0.15
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-0.66 $-0.66 $-0.66

ENVB Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Mar 2022 1 $0.00 $0.00 $0.00
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 1 $0.00 $0.00 $0.00

ENVB Earnings Date & Revenue History

ENVB Earnings History

|
Show More
Show More

ENVB Revenue History

|
Show More
Show More

Enveric Biosciences Next Earnings Date & Report

ENVB Nov 2021 (FQ) Earnings Date & Report Preview

Enveric Biosciences Previous Earnings Dates & Reports

ENVB Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Enveric Biosciences's previous earnings date was Nov 15, 2021 for its fiscal quarter ended Sep 30, 2021.

ENVB's earnings per share (EPS) was $-0.12, beating the consensus analysts forecast of $-0.16 by 25.00%.

The EPS was lower than the previous fiscal quarter (Jun 2021) by 200.00%, and higher than the same period a year before (Sep 2020) by -85.18%.

Revenues were $0.00.

The company reported a net income of $-2.71M.

Free cash flow for the quarter was $-5.37M , compared to $-2.02M last quarter and $-1.00M a year before.

ENVB Previous Earnings Date & Report Recap: Dec 2020 (FY)

Revenues were $39.91M, up by 0.00% from previous year's revenue.

The company reported a net income of $-5.60M.

Enveric Biosciences reported a free cash flow of $-2.54M for its fiscal year, compared to $-2.54M a year ago.

The company ended the fiscal year with $4.88M in total debt. lala